Results 201 to 210 of about 115,437 (312)

Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists [PDF]

, 2017
Trine Tramm, Tina Di Caterino, Anne-Marie B. Jylling, Giedrius Lelkaitis, Anne‐Vibeke Lænkholm, Péter Ragó, Tomasz Piotr Tabor, Maj‐Lis Talman, Emmanouela Vouza   +8 more
openalex   +1 more source

Young Autologous Tumor-infiltrating Lymphocytes [PDF]

, 2020
openaire   +1 more source

Targeting the Notch1‐YY1‐ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8+ T‐Cell‐Driven Cancer Cell Pyroptosis

Advanced Science, EarlyView.
In hepatocellular carcinoma (HCC), aberrantly activated Notch1 signaling induces its target gene YY1, which impairs immunotherapy efficacy by suppressing tumor cell‐ICAM1‐driven T cell activation and the mediated pyroptosis of T cells against tumor cells.
Ke Zhu, Fa‐Peng Zhang, Chao Qin, Zhi‐Xiao Song, Cai‐Ni Yang, Shu‐Sheng Lin, Xian‐Huan Yu, Wen‐Rui Wu, Chao‐Qun Liu, Chao Liu, Lei‐Bo Xu   +10 more
wiley   +1 more source

Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis. [PDF]

Front Immunol
Mukherjee S, Ghosh A, Chakraborty S, Basak U, Mukherjee S, Das T, Sa G.   +6 more
europepmc   +1 more source

Stress‐Programmed Immune Niches Fuel TNFR2+ Treg Activation and Drive Neoadjuvant Chemotherapy Resistance in Breast Cancer

Advanced Science, EarlyView.
Single‐cell sequencing reveals stress‐programmed immune states driving TNFα–TNFR2–mediated Treg activation and therapy resistance in breast cancer, while targeting this axis restores antitumor immunity. ABSTRACT The tumor microenvironment (TME) harbors diverse immune cell states that shape therapeutic outcomes in breast cancer.
Zhibo Shao, Xuliren Wang, Han Zhu, Ling Yao, Qi Zhang, Zihan Zhai, Xinyi Lv, Xinyuan Xia, Yi Zhang, Xinya Lu, Xinyi Quan, Jiawen Yang, Xinwei Li, Jieyi Dong, Zhi‐ming Shao, Ruoxi Wang, Bingqiu Xiu, Jiong Wu, Sheng Chen   +18 more
wiley   +1 more source

918 Functional heterogeneity of CD4+ tumor-infiltrating lymphocytes

Journal for ImmunoTherapy of Cancer, 2023
Marco Donia, Mads H Andersen, Martin Lauss, Göran Jönsson, Arianna Draghi, Katja Harbst, Inge Svane, Torben Lorentzen, Shawez Khan, Mario Presti, Christopher A Chamberlain, Agnete WP Jensen, Michael D Crowther, Anne-Christine K Rasmussen, Benedetta Albieri   +14 more
doaj   +1 more source

Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030). [PDF]

J Natl Cancer Inst
Nader-Marta G, Chu X, Mukhopadhyay S, Abramson VG, Brufsky A, Stringer-Reasor EM, Dent SF, Traina TA, Carey LA, Rimawi MF, Specht JM, Miller KD, Santa-Maria CA, Dasgupta T, Kurt BB, DeMeo M, Krop IE, Tung NM, Schnitt SJ, Tayob N, Mayer EL.   +20 more
europepmc   +1 more source

Tumor Infiltrating Lymphocytes-N2-Transduced [PDF]

, 2020
openaire   +1 more source

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng, Jiaxing Huang, Shengnan Lv, Jian Zhang, Liangliang Zhang, Huan Liu, Yan Liu, Zhen‐An Qiao, Feng Wei, Bao‐Lian Su   +9 more
wiley   +1 more source

Tumor-Infiltrating Lymphocytes Predict Extranodal Extension and Prognosis in Regionally Advanced Oral Cavity Cancer. [PDF]

Diagnostics (Basel)
Lorencin Bulic M, Jurlina M, Müller D, Lijovic L, Mamic M, Luksic I.   +5 more
europepmc   +1 more source